Feng Chenxi, Chen Rongrong, Wang Keer, Wen Chengping, Xu Zhenghao
The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
School of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Ther Adv Chronic Dis. 2021 Feb 12;12:2040622321993438. doi: 10.1177/2040622321993438. eCollection 2021.
GuiZhi-ShaoYao-ZhiMu decoction (GSZD), a traditional Chinese herbal medication, has been frequently used as an add-on medication to methotrexate (MTX) for rheumatoid arthritis (RA) treatment in China. This meta-analysis evaluated the efficacy and safety of adding GSZD to MTX for RA treatment.
We performed a systematic search of , and the (all databases) for English-language studies and , and for Chinese-language studies up to 28 July 2020. Data from selected studies, mainly the response rates and rate of adverse events (AEs), were extracted independently by two authors, and a random-effects model (Mantel-Haenszel method) was used for the meta-analysis.
A total of 14 randomized controlled trials and 1224 patients were included (623 patients in the GSZD + MTX group and 601 patients in the MTX group). For efficacy, the meta-analysis found that combining GSZD with MTX increased the effective rate [relative risk (RR) = 1.24, 95% confidence interval (CI): 1.18-1.30, based on 1069 patients], defined as >30% efficacy, American College of Rheumatology 20, or a decrease of disease activity score 28 >0.6. Adding GSZD reduced the swollen and tender joint counts, the duration of morning stiffness, the levels of C-reactive protein and rheumatoid factor, and erythrocyte sedimentation rate. The adjuvant therapeutic effect of GSZD was independent of the dose of MTX or the combined utilization of other drugs in both groups. For safety, adding GSZD was associated with a lower rate of total AEs (RR = 0.46, 95% CI: 0.26-0.83, based on 615 patients) and gastrointestinal tract AEs (RR = 0.46, 95% CI: 0.24-0.88, based on 537 patients).
Combining GSZD with MTX may be a more efficacious and safer strategy for treating RA compared with MTX alone. Further large studies are warranted to investigate the long-term efficacy and safety of adding GSZD to MTX for RA treatment.
桂枝芍药知母汤(GSZD)是一种传统中药,在中国常用于作为甲氨蝶呤(MTX)治疗类风湿关节炎(RA)的附加药物。本荟萃分析评估了在MTX治疗RA中添加GSZD的疗效和安全性。
我们对截至2020年7月28日的英文研究进行了系统检索,检索了 以及 (所有数据库),对中文研究检索了 以及 。两名作者独立提取所选研究的数据,主要是缓解率和不良事件(AE)发生率,并采用随机效应模型(Mantel-Haenszel方法)进行荟萃分析。
共纳入14项随机对照试验和1224例患者(GSZD + MTX组623例患者,MTX组601例患者)。对于疗效,荟萃分析发现,将GSZD与MTX联合使用可提高有效率[相对危险度(RR)= 1.24,95%置信区间(CI):1.18 - 1.30,基于1069例患者],有效率定义为疗效>30%、美国风湿病学会20标准或疾病活动评分28降低>0.6。添加GSZD可减少肿胀和压痛关节数、晨僵持续时间、C反应蛋白和类风湿因子水平以及红细胞沉降率。在两组中,GSZD的辅助治疗效果与MTX剂量或其他药物的联合使用无关。对于安全性,添加GSZD与较低的总AE发生率(RR = 0.46,95% CI:0.26 - 0.83,基于615例患者)和胃肠道AE发生率(RR = 0.46,95% CI:0.24 - 0.88,基于537例患者)相关。
与单独使用MTX相比,将GSZD与MTX联合使用可能是治疗RA更有效且更安全的策略。有必要进行进一步的大型研究来调查在MTX治疗RA中添加GSZD的长期疗效和安全性。